125 related articles for article (PubMed ID: 15928038)
1. Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression.
Testa U; Riccioni R; Biffoni M; Diverio D; Lo-Coco F; Foà R; Peschle C; Frankel AE
Blood; 2005 Oct; 106(7):2527-9. PubMed ID: 15928038
[TBL] [Abstract][Full Text] [Related]
2. Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity.
Liu TF; Urieto JO; Moore JE; Miller MS; Lowe AC; Thorburn A; Frankel AE
Exp Hematol; 2004 Mar; 32(3):277-81. PubMed ID: 15003313
[TBL] [Abstract][Full Text] [Related]
3. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors.
Hogge DE; Yalcintepe L; Wong SH; Gerhard B; Frankel AE
Clin Cancer Res; 2006 Feb; 12(4):1284-91. PubMed ID: 16489085
[TBL] [Abstract][Full Text] [Related]
4. Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice.
Yalcintepe L; Frankel AE; Hogge DE
Blood; 2006 Nov; 108(10):3530-7. PubMed ID: 16882709
[TBL] [Abstract][Full Text] [Related]
5. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein.
Alexander RL; Ramage J; Kucera GL; Caligiuri MA; Frankel AE
Leuk Res; 2001 Oct; 25(10):875-81. PubMed ID: 11532521
[TBL] [Abstract][Full Text] [Related]
6. In vitro interleukin-3 binding to leukemia cells predicts cytotoxicity of a diphtheria toxin/IL-3 fusion protein.
Alexander RL; Kucera GL; Klein B; Frankel AE
Bioconjug Chem; 2000; 11(4):564-8. PubMed ID: 10898579
[TBL] [Abstract][Full Text] [Related]
7. Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor.
Frankel AE; Ramage J; Kiser M; Alexander R; Kucera G; Miller MS
Protein Eng; 2000 Aug; 13(8):575-81. PubMed ID: 10964987
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia.
Frankel AE; Powell BL; Hall PD; Case LD; Kreitman RJ
Clin Cancer Res; 2002 May; 8(5):1004-13. PubMed ID: 12006512
[TBL] [Abstract][Full Text] [Related]
9. DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia.
Hall PD; Willingham MC; Kreitman RJ; Frankel AE
Leukemia; 1999 Apr; 13(4):629-33. PubMed ID: 10214872
[TBL] [Abstract][Full Text] [Related]
10. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias.
Frankel AE; McCubrey JA; Miller MS; Delatte S; Ramage J; Kiser M; Kucera GL; Alexander RL; Beran M; Tagge EP; Kreitman RJ; Hogge DE
Leukemia; 2000 Apr; 14(4):576-85. PubMed ID: 10764142
[TBL] [Abstract][Full Text] [Related]
11. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.
Feuring-Buske M; Frankel AE; Alexander RL; Gerhard B; Hogge DE
Cancer Res; 2002 Mar; 62(6):1730-6. PubMed ID: 11912147
[TBL] [Abstract][Full Text] [Related]
12. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis.
Testa U; Riccioni R; Militi S; Coccia E; Stellacci E; Samoggia P; Latagliata R; Mariani G; Rossini A; Battistini A; Lo-Coco F; Peschle C
Blood; 2002 Oct; 100(8):2980-8. PubMed ID: 12351411
[TBL] [Abstract][Full Text] [Related]
13. A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia.
Kim HP; Frankel AE; Hogge DE
Leuk Res; 2010 Aug; 34(8):1035-42. PubMed ID: 20137810
[TBL] [Abstract][Full Text] [Related]
14. A urokinase-activated recombinant diphtheria toxin targeting the granulocyte-macrophage colony-stimulating factor receptor is selectively cytotoxic to human acute myeloid leukemia blasts.
Abi-Habib RJ; Liu S; Bugge TH; Leppla SH; Frankel AE
Blood; 2004 Oct; 104(7):2143-8. PubMed ID: 15161668
[TBL] [Abstract][Full Text] [Related]
15. Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice.
Black JH; McCubrey JA; Willingham MC; Ramage J; Hogge DE; Frankel AE
Leukemia; 2003 Jan; 17(1):155-9. PubMed ID: 12529673
[TBL] [Abstract][Full Text] [Related]
16. Toxicology and pharmacokinetics of DT388IL3, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human interleukin 3 (IL3), in cynomolgus monkeys.
Cohen KA; Liu TF; Cline JM; Wagner JD; Hall PD; Frankel AE
Leuk Lymphoma; 2004 Aug; 45(8):1647-56. PubMed ID: 15370220
[TBL] [Abstract][Full Text] [Related]
17. Characterization and receptor specific toxicity of two diphtheria toxin-related interleukin-3 fusion proteins DAB389-mIL-3 and DAB389-(Gly4Ser)2-mIL-3.
Liger D; vanderSpek JC; Gaillard C; Cansier C; Murphy JR; Leboulch P; Gillet D
FEBS Lett; 1997 Apr; 406(1-2):157-61. PubMed ID: 9109408
[TBL] [Abstract][Full Text] [Related]
18. Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein.
Frankel AE; Beran M; Hogge DE; Powell BL; Thorburn A; Chen YQ; Vallera DA
Exp Hematol; 2002 Nov; 30(11):1316-23. PubMed ID: 12423685
[TBL] [Abstract][Full Text] [Related]
19. The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells.
Ramage JG; Vallera DA; Black JH; Aplan PD; Kees UR; Frankel AE
Leuk Res; 2003 Jan; 27(1):79-84. PubMed ID: 12479856
[TBL] [Abstract][Full Text] [Related]
20. Characterization of variant diphtheria toxin-interleukin-3 fusion protein, DTIL3K116W, for phase I clinical trials.
Su Y; Li SY; Ghosh S; Ortiz J; Hogge DE; Frankel AE
Biologicals; 2010 Jan; 38(1):144-9. PubMed ID: 19783458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
